Simplex Trading’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$19.7K Sell
7,300
-1,700
-19% -$3.15K ﹤0.01% 7121
2026
Q1
$10.8K Buy
9,000
+3,100
+53% +$3.77K ﹤0.01% 7300
2025
Q4
$5.8K Buy
5,900
+5,100
+638% +$6.12K ﹤0.01% 7346
2025
Q3
$1K Buy
+800
New +$863 ﹤0.01% 8801
2024
Q4
Sell
-900
Closed -$3K 8824
2024
Q3
$3K Buy
900
+100
+13% +$389 ﹤0.01% 7829
2024
Q2
$2K Sell
800
-500
-38% -$2.19K ﹤0.01% 8262
2024
Q1
$9K Buy
+1,300
New +$8.05K ﹤0.01% 7669
2023
Q3
Sell
-14,900
Closed -$70K 8979
2023
Q2
$70K Sell
14,900
-9,000
-38% -$49.7K ﹤0.01% 5486
2023
Q1
$136K Buy
23,900
+20,100
+529% +$121K ﹤0.01% 4792
2022
Q4
$38K Sell
3,800
-2,100
-36% -$39.4K ﹤0.01% 6198
2022
Q3
$132K Buy
5,900
+3,200
+119% +$92.5K ﹤0.01% 5140
2022
Q2
$66K Sell
2,700
-2,200
-45% -$60.7K ﹤0.01% 6121
2022
Q1
$189K Buy
4,900
+900
+23% +$34.9K ﹤0.01% 5231
2021
Q4
$234K Buy
4,000
+3,200
+400% +$181K ﹤0.01% 4947
2021
Q3
$75K Hold
800
﹤0.01% 7011
2021
Q2
$69K Buy
800
+785
+5,233% +$63.3K ﹤0.01% 7223
2021
Q1
$123K Buy
15
+10
+200% +$958 ﹤0.01% 5445
2020
Q4
$45K Sell
5
-10
-67% -$621 ﹤0.01% 6296
2020
Q3
$59K Sell
15
-33
-69% -$1.15K ﹤0.01% 5445
2020
Q2
$164K Sell
48
-498
-91% -$14.8K ﹤0.01% 4220
2020
Q1
$1.21M Sell
546
-502
-48% -$12.7K ﹤0.01% 1705
2019
Q4
$2.05M Buy
1,048
+309
+42% +$4.91K ﹤0.01% 1460
2019
Q3
$1.15M Sell
739
-773
-51% -$14.8K ﹤0.01% 1800
2019
Q2
$3.07M Sell
1,512
-18
-1% -$324 0.01% 998
2019
Q1
$2.69M Buy
1,530
+1,147
+299% +$18.1K 0.01% 1113
2018
Q4
$491K Sell
383
-288
-43% -$4.02K ﹤0.01% 2254
2018
Q3
$1.09M Buy
671
+131
+24% +$1.55K ﹤0.01% 1794
2018
Q2
$612K Buy
540
+131
+32% +$1.44K ﹤0.01% 2256
2018
Q1
$85K Buy
409
+359
+718% +$3.44K ﹤0.01% 1932
2017
Q4
$8K Buy
50
+45
+900% +$201 ﹤0.01% 4089
2017
Q3
$1K Buy
+5
New +$17 ﹤0.01% 5411

Other funds holding FATE

Simplex Trading's FATE Position: Q2 2026 in Review

Simplex Trading reduced its Fate Therapeutics (FATE) stake by 70% in Q2 2026, selling an estimated $21.4K and leaving 4,866 shares worth $13.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7465.

Simplex Trading first reported a position in FATE in Q3 2017 and has held it in 28 quarters since. The position peaked at $770K in Q3 2020. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Simplex Trading held 4,866 shares of Fate Therapeutics worth $13.1K as of Q2 2026.
  • Simplex Trading sold 11,570 Fate Therapeutics shares in Q2 2026, an estimated $21.4K.
  • Fate Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #7465 holding.
  • Simplex Trading first reported a position in Fate Therapeutics in Q3 2017 and has held it in 28 quarters since.
  • Simplex Trading's Fate Therapeutics position peaked at $770K in Q3 2020.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.